Biochemical Pharmacology:俞强课题组牛蒡子苷元治疗肿瘤机理研究进展

2012-08-08 俞强等 中科院上海药物研究所

  选择性杀伤肿瘤细胞而减轻对正常组织的损伤是目前治疗肿瘤策略所面临的重大挑战。研究表明,由于肿瘤细胞的快速增殖,实体瘤细胞通常处于氧气、葡萄糖或其他营养物质匮乏的状态。因此,靶向葡萄糖缺乏的肿瘤细胞可能会成为选择性杀伤肿瘤细胞的一个新策略。   牛蒡子苷元是临床常用传统中药牛蒡子的主要活性成分。现有研究表明,牛蒡子苷元具有抗肿瘤活性,能够在多种肿瘤模型中有效抑制肿瘤生长

 
选择性杀伤肿瘤细胞而减轻对正常组织的损伤是目前治疗肿瘤策略所面临的重大挑战。研究表明,由于肿瘤细胞的快速增殖,实体瘤细胞通常处于氧气、葡萄糖或其他营养物质匮乏的状态。因此,靶向葡萄糖缺乏的肿瘤细胞可能会成为选择性杀伤肿瘤细胞的一个新策略。
 
牛蒡子苷元是临床常用传统中药牛蒡子的主要活性成分。现有研究表明,牛蒡子苷元具有抗肿瘤活性,能够在多种肿瘤模型中有效抑制肿瘤生长。中科院上海药物研究所俞强课题组对牛蒡子苷元的抗肿瘤机制进行了深入研究,发现在葡萄糖缺乏条件下,牛蒡子苷元通过抑制线粒体呼吸造成肿瘤细胞内ATP水平下降以及活性氧族水平升高,从而促使肿瘤细胞死亡。
 
研究同时还发现,牛蒡子苷元和糖酵解抑制剂2-脱氧-D-葡萄糖联合使用能够选择性杀伤肿瘤细胞,而对正常细胞的毒性较低。
 
该项研究成果为用中药治疗肿瘤提供了新的依据和策略。相关论文已在线发表于Biochemical Pharmacology杂志。
 
该研究工作得到了国家自然科学基金和国家重大科技专项的资助.
 
拓展阅读:牛蒡子苷元,中草药。别名:恶实、蝙蝠刺、大力子、鼠粘子、万把钩、老母猪耳朵。性味功效:种子:味辛、苦,性寒,疏散风热,宣肺透疹,散结解毒。根,味苦、辛,性寒,清热解毒,疏风利咽。 临床应用中牛蒡子与其他中药组成复方制剂治疗肺癌、大肠癌及其他转移性癌,发现有癌肿消失或缩小的现象,并能延长生存期。本药也用于热毒壅盛、气血瘀结的咽喉部肿瘤。此外,还常用治疗感冒、咽喉红肿、流行性腮腺炎、疹出不透、痈疖疮疡、湿疹等。
 
链接:Yuan Gua, Chunting Qia, Xiaoxiao Suna, Xiuquan Mab, Haohao Zhanga, Lihong Huc, Junying Yuand, Qiang Yua.Arctigenin preferentially induces tumor cell death under glucose deprivation by inhibiting cellular energy metabolism.Volume 84, Issue 4, 15 August 2012, Pages 468–476

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
    2013-04-24 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
    2013-03-17 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
    2012-08-27 stfoxst
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
    2012-10-23 yb6560
  8. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1787122, encodeId=78651e87122d1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 24 07:31:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916920, encodeId=73c1191692069, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 17 04:31:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782970, encodeId=ab1d1e8297054, content=<a href='/topic/show?id=39754605d8' target=_blank style='color:#2F92EE;'>#Chemical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4605, encryptionId=39754605d8, topicName=Chemical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Aug 27 10:31:00 CST 2012, time=2012-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908148, encodeId=3f921908148ba, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 13 13:31:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788139, encodeId=7eb61e88139e6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri May 24 14:31:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809200, encodeId=c560180920033, content=<a href='/topic/show?id=20ee829e06c' target=_blank style='color:#2F92EE;'>#肿瘤机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82970, encryptionId=20ee829e06c, topicName=肿瘤机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Tue Mar 19 13:31:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995875, encodeId=47ac19958e574, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 14:31:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788648, encodeId=cd141e886481b, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Nov 27 23:31:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380364, encodeId=22771380364ee, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Aug 10 02:31:00 CST 2012, time=2012-08-10, status=1, ipAttribution=)]